Amyl Therapeutics Secures €8.25 Million in Series A Extension
Amyl Therapeutics, a biotechnology company based in Liège, Belgium, has announced the successful completion of a €8.25 million Series A extension. Amyl Therapeutics is focused on developing a technology platform aimed at treating diseases associated with amyloid fibrils, which are linked to several neurodegenerative conditions.
Investors and Funding Details
The Series A extension was supported by existing investors Noshaq and Merieux Equity Partners. This round also saw participation from new private investors, including family offices and business angels who have chosen to remain undisclosed.
Use of Funds
The funds raised will be directed towards finalizing the development of Amyl Therapeutics' clinical candidate, preparing it for Good Manufacturing Practice (GMP) manufacturing. Additionally, the company plans to generate the necessary preclinical in vivo efficacy and safety data to validate its platform. This funding will also support the expansion of Amyl's laboratory facilities at the LegiaPark life sciences campus in Liège, as well as doubling its research and development team.
Leadership Insights
Pierre Vandepapeliere, the Chief Executive Officer of Amyl Therapeutics, emphasized the importance of this funding round, stating: "This financing is an important endorsement of both our science and our vision." He expressed gratitude for the continued support from investors and public partners, which enables the company to advance to the next critical stage of its development.
Organizational Growth
As part of the organizational growth, one of the new lead family office investors will join Amyl Therapeutics' board of directors, bringing additional expertise and guidance to the company.
Amyl Therapeutics continues to make strides in the biotechnology sector, with this latest funding round paving the way for further development and expansion of its innovative platform.